The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...

Eli Lilly releases data for a new weight-loss drug to tackle obesity : Shots - Health News There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated ...

"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in ...